SCHEMBL23328989

SCHEMBL23328989

Cc1cc(C(C)C)ccc1-c1cnn[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
PTGS1 P23219 2/20 0.37
TRPA1 O75762 1/20 0.37
CACNA1C Q13936 1/20 0.37
METAP2 P50579 1/20 0.33
EIF4A3 P38919 1/20 0.32
PTGS2 P35354 1/20 0.32
HPGD P15428 1/20 0.31
GFER P55789 1/20 0.31
HSD17B10 Q99714 1/20 0.31
IGF1R P08069 2/20 0.31
AURKA O14965 1/20 0.31
DAPK3 O43293 1/20 0.31
JAK2 O60674 1/20 0.31
MAP4K4 O95819 1/20 0.31
PAK4 O96013 1/20 0.31
ABL1 P00519 1/20 0.31
LCK P06239 1/20 0.31
FYN P06241 1/20 0.31
CSF1R P07333 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5020253 0.80 MAPT (0.47) LMNAHPGDNPSR1
SCHEMBL8781205 0.77 NOTUM (0.45) RETDYRK1ALRRK2
SCHEMBL20676163 0.74 LMNA (0.77) LMNAPTGS1TRPA1CACNA1CPTGS2
SCHEMBL23329062 0.74 RAB9A (0.44) HPGDNPSR1TYR
SCHEMBL5020179 0.72 RAB9A (0.44) LMNATRPA1METAP2HPGDHSD17B10
SCHEMBL14448460 0.71 LMNA (0.46) LMNAPTGS1TRPA1CACNA1CMETAP2
SCHEMBL10416092 0.70 LMNA (0.86) LMNAPTGS1TRPA1CACNA1CPTGS2
SCHEMBL25093231 0.70 NPC1 (0.31) NPSR1
SCHEMBL11951625 0.68 LMNA (0.50) LMNAPTGS1TRPA1CACNA1CMETAP2
SCHEMBL18730149 0.68 LMNA (0.50) LMNAPTGS1TRPA1CACNA1CPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO LMNA 4767/4885PTGS1 737/4885TRPA1 4856/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO LMNA 4767/4885PTGS1 737/4885TRPA1 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.